Australian Pharmaceutical Patents Expiring June 2014

Below is a report from IP Organisers (an independent service company of Phillips Ormonde Fitzpatrick) detailing Australian Pharmaceutical Patents (that have been granted extensions) and that are due to expire in the coming month.

This report covers Australian patents whose Extension of Term expires in June 2014.

ip org


Australian Pharmaceutical Patents

Expiring June 2014

Active Ingredient Rizatripan benzoate
Trade Name Maxalt
Chemical Name N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine monobenzoate
Chemical Structure  
Australian Patent AU-C-644939
Expiry Date 8 June 2014
Patent Assignee Merck Sharp & Dohme Limited
Title Imidazole, triazole and tetrazole derivatives
Abstract A class of substituted imidazole, triazole and tetrazole derivatives are selective agonists of 5-HT1-like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated.
Australian Register of Therapeutic Goods ARTG ID 69524
Consumer Medicine Information Maxalt (Rizatriptan benzoate)
Product Information Maxalt (Rizatriptan benzoate)



Active Ingredient Abacavir
Trade Name Ziagen
Chemical Name {(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol
Chemical Structure  
Australian Patent AU-B-633672
Expiry Date 9 June 2014
Patent Assignee ViiV Healthcare UK Limited
Title Therapeutic 6-substituted carbocyclic nucleosides
Abstract The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. The invention also relates to pharmaceutical formulations and processes for the preparation of compounds according to the invention.
Australian Register of Therapeutic Goods ARTG ID 66878ARTG ID 66879
Consumer Medicine Information Ziagen Tablets (Abacavir sulfate)Ziagen Oral Solution (Abacavir sulfate)
Product Information Ziagen (Abacavir sulfate)



Active Ingredient Moxifloxacin
Trade Name Avelox
Chemical Name 1-cyclopropyl-7-[(1S,6S)-2,8-diazabicyclo [4.3.0]non-8-yl]-6-fluoro-8-methoxy-4-oxo-quinoline-3-carboxylic acid
Chemical Structure  
Australian Patent AU-B-671386
Expiry Date 19 June 2014
Patent Assignee Bayer Intellectual Property GmbH
Title Quinolone carboxylic acid derivatives and pharmaceutical formulations containing them
Abstract The invention relates to new quinolone carboxylic acid deriviatives and pharmaceutical formulations containing them.
Australian Register of Therapeutic Goods ARTG ID 75766
Consumer Medicine Information Avelox (Moxifloxacin)
Product Information Avelox (Moxifloxacin)




Recent Pharma-Patent News
from Around the World

[UK] New home for SPCs on UK government portal

“The UK Government’s GOV.UK portal now has an SPC page, “Apply or extend a supplementary protection certificate”, which you can check out here.”


Read More

[Australia] High Court takes Lexapro


“Alphapharm has been granted special leave to appeal to the High Court against the decision in Aspen Pharma Pty Ltd v H  Lundbeck  A/S [2013] FCAFC 129.


Leave was granted in relation to the Full Court’s findings that patentee Lundbeck could rely on section 223 (extensions of time) in respect of its application for an extension of term of a pharmaceutical patent pursuant to section 70.”


Read More


[US] Preliminary Injunctions Post-Mayo and Myriad


“While the effects of the Mayo and Myriad decisions on patent law have been widely discussed, they have recently played a fascinating—and less explored—role in another area of law: preliminary injunctions. In several recent patent cases, the contours of Mayo and Myriad have driven district courts to deny preliminary injunctions on patent eligibility grounds. This has subtly altered the texture of the preliminary injunction standard in patent infringement disputes, causing district courts to place greater emphasis on difficult, scientifically complex questions of patent eligibility at nascent stages of litigation. While time—and appeals—will tell whether this change remains viable, this shift in the preliminary injunction standard provides a fascinating, practical case study as to one law: the law of unintended consequences.”


Read More


[Morocco] Factors influencing anti-asthmatic generic drug consumption in Morocco: 1999-2010


“Despite the introduction of a compulsory insurance scheme called “AMO”, that allows a refund for 69.5% of anti-asthmatic specialties marketed in Morocco, anti-asthmatic generic drug consumption remains limited. The Moroccan market is still largely dominated by the originator drugs with still valid patents.”


Read More


[Hong Kong] Patently Lacking: A Call for Systemic Review of Pharmaceutical Law and Policy — A Case Study of Hong Kong

“This article offers preliminary findings into the pharmaceutical laws and policy of Hong Kong. Applying a framework approach to identifying the linkages between pharmaceutical patents and policy objectives in the areas of public health, medical innovation and pharmaceutical industry development, the article examines the pharmaceutical patent regime as an integrated system of patent and regulatory laws which govern pharmaceutical patents and products and explores the way such provisions operate at a complex intersection of policy objectives, priorities and mandates.”


Read More

 For further information please contact Rodney Chiang-Cruise or Aaron McMillan at IP Organisers Pty Ltd

BAppSc(AppChem) FIPTA

Rodney is the Manager and Team Coordinator of IP Organisers Pty Ltd. He is also a Principal of Phillips Ormonde Fitzpatrick.